Drugs

Dec 24, 2024, 14:29

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma

Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:

“Advanced urothelial carcinoma patients with TSC1 mutations show higher response rates to EV monotherapy (87% vs. 51%), while presence of CDKN2A/B is neg associated with PFS (4.6 vs. 6 ) mo. (Nectin4 is not available).”

Enfortumab

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

Authors: Tanya Jindal et al.

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma

advanced urothelial carcinoma Ajjai Alva Ali Raza Khaki. Amanda Nizam Arnab Basu Cameron Pywell cancer Charles Nguyen Christopher Hoimes Cindy Jiang Deepak Kilari Dimitra Bakaloudi Dory Freeman Emily Lemke Hamid Emamekhoo Joaquim Bellmunt Laura Bukavina Matthew Davidsohn Matthew I. Milowsky Matthew T Campbell Mehmet A Bilen Michael Glover Nancy B. Davis Omar Alhalabi OncoDaily Oncology Pedro C Barata Petros Grivas Rafee Talukder Rohit Bose Sean Evans Shilpa Gupta Sumit A. Shah Tanya Jindal Vadim S Koshkin Woogwang Sim Yousef Zakharia

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

Simon Mooijaart: Patient Perspectives on Antithrombotic Therapy in Advanced Cancer

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?